NEW YORK (GenomeWeb News) - Norwegian company Genpoint has merged with Swedish firm MBS, the companies said today in a joint release.
The companies market DNA-analysis instruments and reagents for clinical diagnostics that have been used for tuberculosis, staph infections, and sexually transmitted diseases.
Erik Hornes, Genpoint's CEO, said the combined companies will continue to work on bacterial infections and will also shift to viral infections and cancer.
The companies said the merger will help establish new positions beyond their footholds in Norway and Sweden and their client base in Finland and Denmark.
The companies are expecting combined 2006 revenue of NOK 8 million ($1.3 million) and 2007 revenue between NOK 15 and NOK 20 million.
Financial terms of the deal were not released.